
    
      This open-label trial is composed of two periods: Induction and Extension. All eligible
      patients will be enrolled into the 12-Week Induction period and receive study medication.
      Patients who complete the Induction period may then be eligible to enter the 100-Week
      Extension period where they will continue to receive study medication.
    
  